Our Pipeline
Therapeutic Candidates
Indications
Preclinical
Phase 1
Phase 2
Phase 3
ERNA-101
Oncology
Triple-Negative Breast Cancer
Platinum-Resistant, TP53-Mutant Ovarian Cancer
ERNA-101
Oncology
Triple-Negative Breast Cancer
Platinum-Resistant, TP53-Mutant Ovarian Cancer